IMAGENS EM HEMATOLOGIA
P53 gene deletion in multiple myeloma
Deleção da gene P53 no mieloma múltiplo
Manoela M. OrtegaI; Mônica B. MeloII; Cármino A. de SouzaI; Irene Lorand-MetzeI; Fernando F. CostaI; Carmen S. P. LimaII
IDepartment of Internal Medicine
IIHaematology and Haemotherapy Centre, State University of Campinas, Campinas, SP, Brazil
Endereço para correspondência Correspondence to Carmen S. P. Lima Hemocentro UNICAMP Cidade Universitária Zeferino Vaz Caixa postal 6198 Cep: 13083-970 Campinas-SP Brazil Tel: (+55 19) 3788-8729 fax: (+55 19) 3788-8600 E-mail: carmenl@unicamp.br
The role of P53 gene abnormalities in the pathogenesis of multiple myeloma (MM) and their potential use as prognostic indicator remains uncertain.1-4 To further define this question, we studied genomic DNA from 50 MM and one plasma cell leukaemia patients by polymerise chain reaction singlestrand conformation polymorphism and sequencing, and fluorescence in situ hybridisation in order to detect P53 mutations and deletions, respectively. Kaplan-Meier survival curves and the log-rank test were used to analyse the survival data.
No P53 mutation was detected in our patients. In contrast, P53 deletion, predominantly monoallelic, was detected in 8 out of 51 (15.7%) patients. Patients with P53 deletions had significantly shorter median overall survival compared with those without a deletion (7.4 vs. 139.0 months, P<0.0001). In univariate regression analysis, P53 deletion was a parameter for predicting shortened survival (P=0.02).
We concluded that P53 mutation might be seen as a prognostic indicator of limited value in MM. In contrast, P53 deletion might be seen as a prognostic indicator of poor outcome. These results have already been accepted for publication in Annals of Hematology and has been submitted to Rev. Bras. Hematol. Hemoter., with the purpose of presenting the images obtained by conventional and molecular cytogenetics analyses performed in study (Figures 1 and 2).
Referências Bibliográficas
1. Avet-Loiseau H, Li JY, Godon C et al. P53 deletions is not a frequent event in multiple myeloma. Br J Haematol 1999;106:717-9.
2. Corradini P, Inghirami G, Astolfi M, et al. Inactivation of tumor suppressor genes, P53 and Rb1 in plasma cell dyscrasias. Leukemia 1994;8:758-67.
3. Drach J, Ackerman J, Fritz E et al. Presence of a P53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemo-therapy. Blood 1998;92:802-9.
4. Owen RG, Davis SAA, Randerson J et al. P53 gene mutations in multiple myeloma. J Clin Pathol Mol Pathol 1997;50:18-20.
Recebido: 15/04/03
Aceito: 02/05/03
Correspondence to
Publication Dates
-
Publication in this collection
11 Dec 2003 -
Date of issue
June 2003
